Unlock instant, AI-driven research and patent intelligence for your innovation.

Monovalent blood-brain barrier shuttling module

A blood-brain barrier, monovalent technology, applied in non-active ingredient medical preparations, antibodies, targeting specific cell fusion, etc., can solve the problems of limiting pharmacological effects, low concentration of antibodies, etc.

Active Publication Date: 2020-04-24
F HOFFMANN LA ROCHE & CO AG
View PDF86 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This would of course limit any pharmacological effect due to the low concentration of the antibody within the CNS

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Monovalent blood-brain barrier shuttling module
  • Monovalent blood-brain barrier shuttling module
  • Monovalent blood-brain barrier shuttling module

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0150] Media and supplements for hCMEC / D3 (see WO 2006 / 056879 and Weksler, B.B. et al., FASEB J. 19 (2005) 1872-1874) were obtained from Lonza. hCMEC / D3 cells (23-29 passage) on collagen-coated coverslips (microscope) or in flasks to confluency.

[0151] For all transcytosis assays, high-density wells (1×10 8 hole / cm 2 ) PET membrane filter inserts (0.4 μm pore size, 12 mm diameter) are / can be used in 12-well cell culture plates. For the apical and basolateral compartments, calculate the medium volume, which is 400 µL and 1600 µL, respectively. Use / can use rat tail collagen I (7.5μg / cm 2 ) followed by coating the apical chamber of the filter insert with fibronectin (5 μg / mL), with each incubation lasting 1 h at RT. For 10-12 days in EBM2 medium, grow hCMEC / D3 cells to a confluent monolayer (~2 × 10 5 cells / cm 2 ). Air filters were / can be blocked in PBS containing 1% BSA for 1 hour or overnight (o / n) before testing and then calibrated in EBM2 for at least 1 hour.

[01...

Embodiment 1

[0564] Immunization of rabbits and mice

[0565] Immunization of mice

[0566] By transdermal administration of 100 μg carrier DNA, followed by electroporation (2 square pulses of 1000 V / cm, duration 0.1 ms, interval 0.125 s; followed by 4 square pulses of 287.5 V / cm, duration 10 ms, interval 0.125 s), using a plasmid expression vector encoding full-length human or macaque TfR to genetically immunize NMRI mice. Mice received 6 or 7 consecutive immunizations on days 0, 14, 28, 42, 56, 70 and 84. The fourth and sixth immunizations were performed using a vector encoding macaque TfR; a vector encoding human TfR was used for all other immunizations. Blood was drawn on days 36, 78 and 92 and serum prepared for titration by ELISA (see below). Select the animal with the highest titer for a boost on day 96: 10 iv 6 Human TF-1 cells or 50 μg recombinant human soluble TfR lacking the helical domain (human TfR extracellular domain starting at Leu122 and ending at Asn608, expressed i...

Embodiment 2

[0572] B-cell clones from rabbits

[0573] Isolation of Rabbit Peripheral Blood Mononuclear Cells (PBMC)

[0574] In total, blood samples were obtained from 6 animals (2 wild type (wt) rabbits and 4 transgenic (tg) rabbits). These rabbits were derived from 2 different rounds of immunization: the first round of immunizations used 2 wt and 2 tg rabbits, while the second round of immunizations used 2 tg rabbits (see also example "Immunization of rabbits"). Whole blood containing EDTA was diluted two-fold with 1×PBS (PAA, Pasching, Austria), followed by densitometry using Lympholyte Mammal (Cedarlane Laboratories, Burlington, Ontario, Canada) according to the manufacturer's instructions. centrifugal. PBMCs were washed twice with 1×PBS.

[0575] EL-4B5 medium

[0576] Supplemented with 10% FCS (Hyclone, Logan, UT, USA), 2mM glutamine, 1% penicillin / streptomycin solution (PAA, Pasching, Austria), 2mM sodium pyruvate, 10mM HEPES (PAN Biotech, Aidenbach, Germany ) and 0.05 mM...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A blood-brain barrier shuttling module comprising a brain effector entity, an adaptor and a monovalent binding entity that binds to a blood-brain barrier receptor is disclosed in the invention, wherein the adaptor couples the effector entity to the monovalent binding entity that binds to the blood-brain barrier receptor, and the monovalent binding entity does not comprise variable domains of anti-transferrin receptor antibodies 8D3 (SEQ ID NO:01 and SEQ ID NO:02) or variable domains of variant anti-transferrin receptor antibodies 8D3v (SEQ ID NO:01 and SEQ ID NO:03).

Description

[0001] This application is a divisional application of the Chinese patent application 201480072065.5 (PCT / EP2014 / 079353) with the filing date of December 29, 2014 and the title of the invention is "Monovalent Blood Brain Barrier Shuttle Module". [0002] field of invention [0003] The present invention relates to a blood-brain barrier shuttle module that has a binding specificity that specifically binds a blood-brain barrier receptor (BBBR) and is monovalent with respect to this binding specificity; also relates to the use of this construct as a blood-brain barrier Brain barrier shuttle bodies and methods for the treatment of neurological diseases. Background technique [0004] Brain penetration of neurological disease drugs, e.g., large biotherapeutics or small molecules with low brain penetration, is limited by the extensive impermeable blood-brain barrier (BBB) ​​and other cells in the neurovascular unit (NUV) Strict restrictions on components. A number of strategies to ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28C07K16/18A61K47/68A61P25/00A61P25/28
CPCC07K16/18A61K2039/505C07K2317/31C07K2317/35C07K2319/33C07K16/2881A61P25/00A61P43/00A61K39/395A61K47/64A61K47/6849C07K2317/622C07K16/28C07K2317/55C07K2317/56
Inventor P·鲁格尔G·蒂芬塔勒E·默斯纳J·尼韦纳A·胡根马特尔邵翠英F·罗斯徐刚
Owner F HOFFMANN LA ROCHE & CO AG